Home Clinical Utility of Free Drug Monitoring
Article
Licensed
Unlicensed Requires Authentication

Clinical Utility of Free Drug Monitoring

  • Amitava Dasgupta
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 40 Issue 10

Abstract

Most drugs are bound to serum proteins to a various degree. Only unbound or free drug is pharmacologically active. Usually total drug is measured for therapeutic monitoring because there is equilibrium between bound and free drugs, and concentration of free drug can be predicted from total drug concentration. However, under certain conditions this equilibrium is disturbed and the measured free drug concentration can be significantly higher than expected from total drug concentrations, especially for strongly protein-bound drugs. In such case a patient may experience drug toxicity even if the total drug concentration is within the therapeutic range. Conditions like uremia, liver disease and hypoalbuminemia can lead to significant increases in free drug concentration. Therefore, monitoring free phenytoin and free valproic acid is recommended in these patients. Drug-drug interactions can also lead to a disproportionate increase in free drug concentration. One strongly protein-bound drug can significantly displace another strongly proteinbound drug if both drugs share the same binding site. Several over-the-counter pain medications such as salicylate, naproxen, and ibuprofen can cause significant displacement of both phenytoin and valproic acid from albumin binding site. Interestingly, such interactions are absent in uremic patients. Elderly patients may have increased free phenytoin or valproic acid due to hypoalbuminemia. Elevated free phenytoin concentrations have also been reported in patients with AIDS. Although digoxin is 25% bound to protein, monitoring free digoxin is useful in patients with elevated endogenous digoxin-like immunoreactive substances or in patients overdosed with digoxin and being treated with digibind. Monitoring free digoxin can also eliminate interference of Chinese medicines Chan Su and Danshen in serum digoxin measurement by certain immunoassays. However, free drug monitoring is not a routine procedure in clinical laboratories due to technical difficulties and lack of established reference ranges for free drugs.

:
Published Online: 2005-06-01
Published in Print: 2002-10-29

Copyright (c) 2002 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. The 9th Asian Pacific Congress of Clinical Biochemistry
  2. Circulating DNA in Plasma and Serum: Biology, Preanalytical Issues and Diagnostic Applications
  3. Role of Steroid Hormones and Growth Factors in Breast Cancer
  4. Gene Polymorphism and Coronary Risk Factors in Indian Population
  5. Clinical Utility of Free Drug Monitoring
  6. Telomerase – a Potential Molecular Marker of Lung and Cervical Cancer
  7. Association of Polymorphisms in the Collagen Region of Human SP-A1 and SP-A2 Genes with Pulmonary Tuberculosis in Indian Population
  8. Effect of Hemodialysis on the Oxidative Stress and Antioxidants
  9. Total Iron Binding Capacity and Transferrin Concentration in the Assessment of Iron Status
  10. Increased Levels of Osteoprotegerin in Hemodialysis Patients
  11. Levels of Testosterone, Allopregnanolone and Homocysteine in Severe Hypothyroidism
  12. The Levels of Serum Vitamin C, Malonyldialdehyde and Erythrocyte Reduced Glutathione in Chronic Obstructive Pulmonary Disease and in Healthy Smokers
  13. Highly Specific, Simple and Rapid Method for the Determination of Malondialdehyde in Blood Using High-Performance Liquid Chromatography
  14. Precision and Accuracy of a HPLC Method for Measurement of Fecal Porphyrin Concentrations
  15. Continuous Age-Dependent Reference Ranges for Thyroid Hormones in Neonates, Infants, Children and Adolescents Established Using the ADVIA(r) Centaur(tm) Analyzer
  16. Diagnostic Value of Various Urine Tests in the Jordanian Population with Urinary Tract Infection
  17. Performance Evaluation of the Precision™ PCx™ Point-of-Care Blood Glucose Analyzer Using Discriminant Ratio Methodology
  18. Clinical Evaluation of a New Automated Anti-dsDNA Fluorescent Immunoassay
  19. Upper Reference Limits for Urinary Catecholamines, Metanephrines and 3-Methoxy-4-Hydroxymandelic Acid in Hypertensive Patients
  20. Growth Hormone Immunoassays: Proposal to Reduce Interlaboratory Variability
  21. Poetry, Images and Visions: William Blake
  22. Meetings and Awards
Downloaded on 20.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2002.172/html
Scroll to top button